Olopatadine Eye Drops and Allergy Skin Testing
Allergic Rhinitis, Allergic Conjunctivitis
About this trial
This is an interventional diagnostic trial for Allergic Rhinitis focused on measuring allergy, skin testing, eye drops, antihistamines
Eligibility Criteria
Inclusion Criteria:
- Adults aged 18 to 75 years
- Healthy volunteers (no major illnesses or active symptoms)
Exclusion Criteria:
- Known allergy or hypersensitivity to the drugs or components
- Pregnant or nursing women
- Women wishing to become pregnant during the study's duration
- Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
- Dermatographism as evidenced on skin testing on visit 1
- Chronic urticaria active within the past 6 months
- Severe hypertension
- Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
- Inability to provide informed consent
Sites / Locations
- Vanderbilt Asthma, Sinus and Allergy Program Research
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
olopatadine then placebo
placebo then olopatadine
participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days